Â鶹ԭ´´

His current research aims to delineate the role of exosomes-associated cargo bioactive molecules as a trojan horse in altering oncologic pathways in tumor and stromal cells to promote cancer progression and metastasis using tissue culture, preclinical model, and human specimens. The findings from his research are of great asset to have successfully competed for NIH support. The ultimate goal of his ongoing research is to utilize different therapeutic strategies for reducing drug resistance and improving the survival of patients with malignant diseases such as prostate cancer and melanoma. One of these strategies is to elucidate the underlying molecular mechanisms of aggressive phenotypes of tumors and discover specific and efficient therapeutic targets. In the same context, there is a critical need for the discovery of novel and reliable biomarkers that can stratify cancer patients according to their pathological stages, response to certain therapeutics, tumor relapse and other clinical outcomes.